title: [Association of HER2 protein expression with clinicopathologic features and prognosis in Chinese patients with gastric carcinoma].
abstract: OBJECTIVE
  To evaluate the epidemiological status of HER2 protein expression in Chinese patients with gastric carcinoma, and to study its clinical and prognostic significance and the association with the clinicopathological features.
  
  
  METHODS
  The clinical data were reviewed in 860 patients with gastric carcinoma admitted to Guangdong General Hospital from 2003 to 2010. The HER2 status was evaluated using immunohistochemistry (IHC). The modified HercepTest scoring criterion was used to assess HER2 protein expression. The association between HER2 expression and clinicopathological features was analyzed by χ(2) test. Kaplan-Meier analysis, log-rank test and Cox regression model were used for the survival analysis.
  
  
  RESULTS
  The median age of the patients was 59 years, and the male-to-female ratio was 2.06:1. Positive expression of HER2 protein (3+) was found in 77 (9.0%) cases of gastric carcinoma, and in 69 (8.9%) advanced gastric cancers. There was significantly positive association between HER2 over-expression and tumor differentiation, Lauren classification and WHO classification. No significant association was observed between HER2 protein expression and patients' age, gender, tumor location and clinical stage. There was no statistically significant difference in survival rate between patients with positive HER2 expression and negative ones.
  
  
  CONCLUSIONS
  Though there was significantly positive association between HER2 expression status and tumor differentiation, histological type, it may be of limited prognostic value in gastric cancer patients.
authors.affiliation: Department of Pathology, Guangdong General Hospital, Guangzhou 510080, China.
authors.forename: Hong-mei
authors.initials: HM
authors.lastname: Wu
authors.forename: Yan-hui
authors.initials: YH
authors.lastname: Liu
authors.forename: Feng
authors.initials: F
authors.lastname: Lin
authors.forename: Fang-ping
authors.initials: FP
authors.lastname: Xu
authors.forename: Dong-lan
authors.initials: DL
authors.lastname: Luo
authors.forename: Fen
authors.initials: F
authors.lastname: Zhang
authors.forename: Heng-guo
authors.initials: HG
authors.lastname: Zhuang
authors.forename: Xin-lan
authors.initials: XL
authors.lastname: Luo
authors.forename: Wu-lin
authors.initials: WL
authors.lastname: Wu
authors.forename: Xing-tao
authors.initials: XT
authors.lastname: Lin
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D000231:Adenocarcinoma, Papillary / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D018279:Carcinoma, Signet Ring Cell / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate; D055815:Young Adult
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human